凝血酸，氨甲环酸

凝血酸，氨甲环酸用途

Tranexamic acid(Transamin)能阻断纤溶酶的赖氨酸结合位点和弹性蛋白酶来源的纤维蛋白溶酶原片段。

点击显示

凝血酸，氨甲环酸作用

传明酸是一种蛋白酶抑制剂，能抑制蛋白酶对肽键水解的催化作用，从而阻止了如发源性蛋白酶等酶的活性，进而抑制了黑斑部位的表皮细胞机能的混乱，并且抑制黑色素增强因子群，再彻底断绝因为紫外线照射而形成的黑色素发生的途径。即让黑斑不再变浓、扩大及增加，从而能有效地防止和改善皮肤的色素沉积。比起一般的M白成分，传明酸拥有高稳定、耐酸碱度、不容易受温度环境影响、不需载体保护、不受传输系统影响破坏、无刺激的特性。

点击显示

凝血酸，氨甲环酸名称

[ CAS 号 ]:
1197-18-8

[ 中文名 ]:
反-4-(氨甲基)环己烷甲酸

[ 英文名 ]:
Tranexamic acid

[中文别名 ]:

[英文别名 ]:

trans-Tramadol hydrochloride
Amstat
trans-4-(Aminomethyl)cyclohexane-carboxylic acid
UNII:9N7R477WCK
Tramadol hydrochloride
tranexamic acid
Tranexamic EP Impurity B
trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid
Tramadol HCL

凝血酸，氨甲环酸生物活性

[ 描述 ]:

Tranexamic acid(Transamin)能阻断纤溶酶的赖氨酸结合位点和弹性蛋白酶来源的纤维蛋白溶酶原片段。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

研究领域 >> 心血管疾病

[参考文献]

[1]. Bhat A, et al. Tranexamic acid overdosage-induced generalized seizure in renal failure. Saudi J Kidney Dis Transpl. 2014 Jan-Feb;25(1):130-2.

[2]. Couturier R, et al. Continuous or discontinuous tranexamic acid effectively inhibits fibrinolysis in children undergoing cardiac surgery with cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2014 Jan 13.

[相关活性小分子]

凝血酸，氨甲环酸物理化学性质

[ 密度 ]:
1.1±0.1 g/cm3

[ 沸点 ]:
300.2±15.0 °C at 760 mmHg

[ 熔点 ]:
>300 °C(lit.)

[ 分子式 ]:
C₈H₁₅NO₂

[ 分子量 ]:
157.210

[ 闪点 ]:
135.4±20.4 °C

[ 精确质量 ]:
157.110275

[ PSA ]:
63.32000

[ LogP ]:
0.31

[ 外观性状 ]:
白色结晶粉末

[ 蒸汽压 ]:
0.0±1.3 mmHg at 25°C

[ 折射率 ]:
1.497

[ 储存条件 ]:
库房通风低温干燥

[ 水溶解性 ]:
1G/6ML

凝血酸，氨甲环酸MSDS

详细MSDS(安全技术说明书)

凝血酸，氨甲环酸毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: GU8400000

CHEMICAL NAME :: Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans-

CAS REGISTRY NUMBER :: 1197-18-8

BEILSTEIN REFERENCE NO. :: 2207452

LAST UPDATED :: 199612

DATA ITEMS CITED :: 13

MOLECULAR FORMULA :: C8-H15-N-O2

MOLECULAR WEIGHT :: 157.24

WISWESSER LINE NOTATION :: L6TJ AVQ D1Z -T

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 4620 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: APTOA6 Acta Pharmacologica et Toxicologica. (Copenhagen, Denmark) V.1-59, 1945-86. For publisher information, see PHTOEH Volume(issue)/page/year: 22,340,1965

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >10 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 4200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 85IRAK "Modern Pharmaceuticals of Japan, V," Tokyo, Japan Pharmaceutical, Medical and Dental Supply Exporters' Assoc., 1975 Volume(issue)/page/year: -,108,1975

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 5310 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1350 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >5 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 1110 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Bird - chicken

DOSE/DURATION :: >10 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,389,1971 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 624 gm/kg/26W-I

TOXIC EFFECTS :: Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,395,1971 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 305 gm/kg

SEX/DURATION :: female 40 day(s) pre-mating female 1-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

REFERENCE :: APTOA6 Acta Pharmacologica et Toxicologica. (Copenhagen, Denmark) V.1-59, 1945-86. For publisher information, see PHTOEH Volume(issue)/page/year: 22,340,1965

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 9 mg/kg

SEX/DURATION :: female 9-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,415,1971

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 9 mg/kg

SEX/DURATION :: female 7-12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,415,1971

点击显示

凝血酸，氨甲环酸安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H315-H319-H335

[ 警示性声明 ]:
P305 + P351 + P338

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xi:Irritant;

[ 风险声明 (欧洲) ]:
R36/37/38

[ 安全声明 (欧洲) ]:
26-36-37/39

[ 危险品运输编码 ]:
UN 1993 3/PG 2

[ WGK德国 ]:
2

[ RTECS号 ]:
GU8400000

[ 包装等级 ]:
II

[ 危险类别 ]:
3

[ 海关编码 ]:
2922499990

凝血酸，氨甲环酸合成路线

详细合成路线

凝血酸，氨甲环酸上下游产品

凝血酸，氨甲环酸上游产品

凝血酸，氨甲环酸下游产品

凝血酸，氨甲环酸制备

1.由对氨甲基苯甲酸经铂催化剂氢化制备，在氢氧化钡溶液中转化为反式。

点击显示

凝血酸，氨甲环酸海关

[ 海关编码 ]: 2922499990

[ 中文概述 ]:
2922499990 其他氨基酸及其酯及它们的盐（含有一种以上含氧基的除外）. 增值税率:17.0% 退税率:9.0% 监管条件:AB(入境货物通关单,出境货物通关单) 最惠国关税:6.5% 普通关税:30.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乙醇胺及其盐应报明色度, 乙醇胺及其盐应报明包装

[ 监管条件 ]: A.入境货物通关单 B.出境货物通关单

[ 检验检疫 ]: P.进境动植物、动植物产品检疫 Q.出境动植物、动植物产品检疫 R.进口食品卫生监督检验 S.出口食品卫生监督检验 M.进口商品检验 N.出口商品检验

[ Summary ]:
HS:2922499990 other amino-acids, other than those containing more than one kind of oxygen function, and their esters; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:6.5% General tariff:30.0%

凝血酸，氨甲环酸文献

Long-Term Mild, rather than Intense, Exercise Enhances Adult Hippocampal Neurogenesis and Greatly Changes the Transcriptomic Profile of the Hippocampus.

PLoS ONE 10 , e0128720, (2015)

Our six-week treadmill running training (forced exercise) model has revealed that mild exercise (ME) with an intensity below the lactate threshold (LT) is sufficient to enhance spatial memory, while i...

Design, Synthesis, and Photophysical Properties of Pyrroloquinoline-Based Compounds Showing Strong Blue Fluorescence as Potential Dyes for Biomedical Applications.

ChemMedChem 10 , 1846-62, (2015)

A small library of 3-ethylpyrrolo[3,2-f]quinoline derivatives was synthesized to identify a novel class of dyes for use in biological studies. According to the spectroscopic analyses performed to eval...

Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism.

Acta Pharmacol. Sin. 35(6) , 846-52, (2014)

Lapatinib is a dual inhibitor of EGFR and human epidermal growth factor receptor 2 (HER2), and used to treat advanced breast cancer. To overcome its poor water solubility, we constructed lapatinib-inc...

更多文献

凝血酸，氨甲环酸

凝血酸，氨甲环酸用途

凝血酸，氨甲环酸作用

凝血酸，氨甲环酸名称

凝血酸，氨甲环酸生物活性

凝血酸，氨甲环酸物理化学性质

凝血酸，氨甲环酸MSDS

详细MSDS(安全技术说明书)

凝血酸，氨甲环酸毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

凝血酸，氨甲环酸安全信息

凝血酸，氨甲环酸合成路线

详细合成路线

凝血酸，氨甲环酸上下游产品

凝血酸，氨甲环酸上游产品

凝血酸，氨甲环酸下游产品

凝血酸，氨甲环酸制备

凝血酸，氨甲环酸海关

凝血酸，氨甲环酸文献

相关化工产品/化学物质：

相关药品：

推荐生产厂家/供应商：

相关化合物